{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:53:37Z","timestamp":1761818017193,"version":"build-2065373602"},"reference-count":94,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jgo.2019.07.025","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T08:07:27Z","timestamp":1565597247000},"page":"41-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma \u2013 Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007\u20132015"],"prefix":"10.1016","volume":"11","author":[{"given":"Vicki A.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustina","family":"Ogbonnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Raju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Hennenfent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Galaznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2019.07.025_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2019.07.025_bb0010","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0015","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0020","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V116.21.589.589","article-title":"R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients: Long-term follow-up of intergroup E4494\/C9793","volume":"116","author":"Morrison","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdv018","article-title":"Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary","volume":"26","author":"Morrison","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2019.07.025_bb0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","article-title":"Diffuse Large B-Cell Lymphoma Version 1.2016","volume":"14","author":"Zelenetz","year":"2016","journal-title":"J Natl Comp Cancer Network"},{"issue":"2","key":"10.1016\/j.jgo.2019.07.025_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000444625","article-title":"Long-term follow-up of a phase II trial of six cycles of dose-dense R-CHOP-14 for first-line treatment of diffuse large B-cell lymphoma in young and elderly patients","volume":"136","author":"Gonzalez-Barca","year":"2016","journal-title":"Acta Haematol"},{"issue":"Suppl. 5","key":"10.1016\/j.jgo.2019.07.025_bb0050","first-page":"v117","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Brit J Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2019.07.025_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trail (MInT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2019.07.025_bb0065","doi-asserted-by":"crossref","first-page":"e0123978","DOI":"10.1371\/journal.pone.0123978","article-title":"Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP-21 or R-CHOP-14","volume":"10","author":"Gutierrez","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jgo.2019.07.025_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00277-015-2514-9","article-title":"Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma","volume":"95","author":"Utsu","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0080","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0085","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2016.67.2980","article-title":"Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy on high-risk patients with diffuse large B-cell lymphoma","volume":"33","author":"Cortelazzo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0090","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjh.14399","article-title":"Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish lymphoma registry study","volume":"175","author":"Melen","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0095","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomized phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jgo.2019.07.025_bb0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.V128.22.469.469","article-title":"Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jgo.2019.07.025_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.jgo.2019.07.025_bb0110","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jgo.2019.07.025_bb0115","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0120","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large N-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2019.07.025_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.clml.2017.10.007","article-title":"Advances in diagnosis and management of diffuse large B-cell lymphoma","volume":"17","author":"Cabanillas","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jgo.2019.07.025_bb0130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-na\u00efve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomized phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5 suppl","key":"10.1016\/j.jgo.2019.07.025_bb0135","volume":"32","author":"Younes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2019.07.025_bb0140","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell type than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2019.07.025_bb0145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2019.07.025_bb0150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0155","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cncr.30173","article-title":"Management strategies and outcome for very elderly patients with diffuse large B-cell lymphoma","volume":"122","author":"Chihara","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2019.07.025_bb0160","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"Muller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0165","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jgo.2019.07.025_bb0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clml.2015.06.005","article-title":"Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review","volume":"15","author":"Crozier","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.jgo.2019.07.025_bb0175","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3109\/10428194.2015.1010078","article-title":"A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish lymphoma registry","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.jgo.2019.07.025_bb0180","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.3109\/10428194.2015.1022771","article-title":"Is 70 the new 60? New international prognostic index with an older age cut-off for diffuse large B-cell lymphoma","volume":"56","author":"Mikhaeel","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jgo.2019.07.025_bb0185","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4143\/crt.2017.172","article-title":"Multicenter retrospective analysis of clinical characteristics, treatment patterns, and outcomes in very elderly patients with diffuse large B-cell lymphoma: the Korean cancer study group LY16-01","volume":"50","author":"Choi","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.jgo.2019.07.025_bb0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clml.2016.06.003","article-title":"Diffuse large B-cell lymphoma in the elderly: real world outcomes of immunochemotherapy in Asian population","volume":"16","author":"Byun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jgo.2019.07.025_bb0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2447","article-title":"Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with \u201cstandard\u201d immunochemotherapy: a large retrospective study from 4 institutions","volume":"36","author":"Gobba","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/imj.12889","article-title":"Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis","author":"Millar","year":"2015","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.jgo.2019.07.025_bb0205","first-page":"427","article-title":"Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma","volume":"58","author":"Takahashi","year":"2017","journal-title":"Jap J Clin Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0210","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3904\/kjim.2015.30.5.684","article-title":"Clinical characteristics and outcomes in diffuse large B cell lymphoma patients agedn70 years and older; a single-center experience with a literature review","volume":"30","author":"Jung","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jgo.2019.07.025_bb0215","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","article-title":"Oitcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHK RICOVER-60 trial","volume":"28","author":"Kuhnl","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0220","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/ejh.13068","article-title":"Role of rephrase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma","volume":"100","author":"Lakshmaiah","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0225","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0230","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.12459","article-title":"Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: consortium for improving survival of lymphoma study (CISL)","volume":"94","author":"Jung","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0235","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0240","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicenter, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0245","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10147-015-0912-6","article-title":"Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced dose chemotherapy","volume":"21","author":"Iioka","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2019.07.025_bb0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10428194.2014.903589","article-title":"Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile","volume":"56","author":"Tien","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in the United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2019.07.025_bb0260","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4143\/crt.2014.339","article-title":"Reduced dose intensities of doxorubicin in elderly patients with DLBCL in rituximab era","volume":"48","author":"Ha","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jgo.2019.07.025_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9817606","article-title":"Comparison of three chemotherapy regimens in elderly patients with diffuse large B-cell lymphoma: experience at a single national reference center in Mexico","author":"Nolasco-Medina","year":"2016","journal-title":"BioMed Res Internatl"},{"issue":"8","key":"10.1016\/j.jgo.2019.07.025_bb0270","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.clml.2015.03.008","article-title":"Nonpegylated liposomal doxorubicin as a component of R-CHOP is an effective and safe alternative to conventional doxorubicin in the treatment of patients with diffuse large B-cell lymphoma and preexisting cardiac diseases","volume":"15","author":"Rohlfing","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jgo.2019.07.025_bb0275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonoegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2019.07.025_bb0280","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3109\/10428194.2015.1096356","article-title":"Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria","volume":"57","author":"Rashidi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0285","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"Do novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0290","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0295","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13069","article-title":"Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma","volume":"11","author":"Cheng","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0300","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in fraIl elderly patients aged 80 or over with diffuse large B-cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.jgo.2019.07.025_bb0310","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0315","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0320","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2016.255","article-title":"A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high\/high-intermediate risk diffuse large B-cell lymphoma","volume":"31","author":"Reddy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2019.07.025_bb0325","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0330","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2019.07.025_bb0335","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/10428194.2015.1045898","article-title":"A randomized phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma","volume":"57","author":"Hainsworth","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0340","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1038\/bcj.2017.57","article-title":"High rate of event-free survival at 24 months with everolimus\/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTGNN1085 (Alliance)","volume":"7","author":"Witzig","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jgo.2019.07.025_bb0345","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(16)30168-5","article-title":"Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial","volume":"4","author":"Kraeber-Bodere","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.29","article-title":"Short-course R-CHOP followed by 90Y-Ibritotumumab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results","volume":"6","author":"Stefoni","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jgo.2019.07.025_bb0355","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24819","article-title":"Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"92","author":"Saygin","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0360","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00277-017-3170-z","article-title":"Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B-cell lymphoma? The prognostic significance of comorbidities","volume":"97","author":"Antic","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0365","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2019.07.025_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.56.43","article-title":"Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients","volume":"6","author":"Naito","year":"2016","journal-title":"J Clin Exp Hematop"},{"issue":"4","key":"10.1016\/j.jgo.2019.07.025_bb0375","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173vpatients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jgo.2019.07.025_bb0380","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/10428194.2014.966246","article-title":"Geriatric assessment in older adults with aggressive lymphoma: growing evidence and new emerging questions","volume":"56","author":"Goede","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0385","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3109\/10428194.2014.935364","article-title":"Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma","volume":"56","author":"Aaldriks","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0390","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CCO.0000000000000394","article-title":"Rational therapeutic choice for older patients with lymphoma","volume":"29","author":"Bronn","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2019.07.025_bb0395","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","article-title":"Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.07.025_bb0400","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.12608","article-title":"Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for \u201cunfit\u201d patients classified by comprehensive geriatric assessment","volume":"96","author":"Yoshida","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0405","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00277-018-3273-1","article-title":"Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B-cell lymphoma","volume":"97","author":"Kanemasa","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jgo.2019.07.025_bb0410","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","article-title":"Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma","volume":"14","author":"Olszewski","year":"2016","journal-title":"J Natl Comp Cancer Network"},{"issue":"7","key":"10.1016\/j.jgo.2019.07.025_bb0415","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3109\/10428194.2014.979412","article-title":"Bodynmass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era","volume":"56","author":"Sarkozy","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0420","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.14702","article-title":"Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases","volume":"178","author":"Boyle","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jgo.2019.07.025_bb0425","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/10428194.2016.1257793","article-title":"Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China","volume":"58","author":"Li","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jcsm.12115","article-title":"Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"7","author":"Go","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jgo.2019.07.025_bb0435","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00277-017-2958-1","article-title":"Impact of cachexia on outcomes in aggressive lymphomas","volume":"96","author":"Karmali","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0440","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00277-015-2499-4","article-title":"Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma","volume":"94","author":"Nakamura","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0445","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.24465","article-title":"Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy","volume":"91","author":"Xiao","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0450","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12185-016-2052-9","article-title":"Low prognostic nutritional index predicts poor outcome in with diffuse large B-cell lymphoma treated with R-CHOP","volume":"104","author":"Zhou","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0455","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10198-016-0775-4","article-title":"Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort","volume":"18","author":"Wang","year":"2017","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jgo.2019.07.025_bb0460","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","article-title":"Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793, ECOG-SWOG 4494)","volume":"58","author":"Morrison","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.07.025_bb0465","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2019.07.025_bb0470","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819302267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819302267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:50:49Z","timestamp":1761817849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406819302267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1879406819302267"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2019.07.025","relation":{},"ISSN":["1879-4068"],"issn-type":[{"type":"print","value":"1879-4068"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma \u2013 Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007\u20132015","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2019.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}